{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:55:05Z","timestamp":1756572905935},"reference-count":27,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2012]]},"DOI":"10.2169\/internalmedicine.51.7927","type":"journal-article","created":{"date-parts":[[2012,10,14]],"date-time":"2012-10-14T23:22:42Z","timestamp":1350256962000},"page":"2857-2862","source":"Crossref","is-referenced-by-count":8,"title":["Comparison of Acute Hemodynamic Effects of Aerosolized Iloprost and Inhaled Nitric Oxide in Adult Congenital Heart Disease with Severe Pulmonary Arterial Hypertension"],"prefix":"10.2169","volume":"51","author":[{"given":"Zhang","family":"Caojin","sequence":"first","affiliation":[{"name":"Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Yigao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Wenhui","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Chunli","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Xinsheng","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong General Hospital & Guangdong Cardiovascular Institute, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119: 2250-2294, 2009."},{"key":"2","unstructured":"2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30: 2493-2537, 2009."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Miller OI, Tang SF, Keech A, Celermajer DS. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 346: 51-52, 1995.","DOI":"10.1016\/S0140-6736(95)92681-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 153: 1985-1987, 1996.","DOI":"10.1164\/ajrccm.153.6.8665066"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00494-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Limsuwan A, Khosithseth A, Wanichkul S, Khowsathit P. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. Catheter Cardiovasc Interv 73: 98-104, 2009.","DOI":"10.1002\/ccd.21793"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 124: 820-824, 1996.","DOI":"10.7326\/0003-4819-124-9-199605010-00006"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 132: 435-443, 2000.","DOI":"10.7326\/0003-4819-132-6-200003210-00003"},{"key":"9","doi-asserted-by":"crossref","unstructured":"10. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51: 161-169, 2008.","DOI":"10.1016\/j.jacc.2007.09.031"},{"key":"10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.190690"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq249"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13. Selzer A, Sudrann RB. Reliability of the determination of cardiac output in man by means of the Fick principle. Circ Res 6: 485-490, 1958.","DOI":"10.1161\/01.RES.6.4.485"},{"key":"13","doi-asserted-by":"crossref","unstructured":"14. Jing ZC, Jiang X, Han ZY, et al. Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur Respir J 33: 1354-1360, 2009.","DOI":"10.1183\/09031936.00169608"},{"key":"14","doi-asserted-by":"crossref","unstructured":"15. Opitz CF, Rubin LJ. Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Eur Respir J 33: 1247-1249, 2009.","DOI":"10.1183\/09031936.00033809"},{"key":"15","doi-asserted-by":"crossref","unstructured":"17. Mereles D, Ewert R, Lodziewski S, et al. Effect of inhaled iloprost during off-medication time in patients with pulmonary arterial hypertension. Respiration 74: 498-502, 2007.","DOI":"10.1159\/000101953"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020204"},{"key":"17","doi-asserted-by":"crossref","unstructured":"19. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 174: 1257-1263, 2006.","DOI":"10.1164\/rccm.200603-358OC"},{"key":"18","doi-asserted-by":"crossref","unstructured":"20. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-termintravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 80: 151-155, 1998.","DOI":"10.1136\/hrt.80.2.151"},{"key":"19","doi-asserted-by":"crossref","unstructured":"21. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 26: 1895-1902, 2005.","DOI":"10.1093\/eurheartj\/ehi283"},{"key":"20","unstructured":"22. Durongpisitkul K, Jakrapanichakul D, Laohaprasitiporn D, Soongswang J, Chanthong P, Nana A. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease. J Med Assoc Thai 88 (Suppl 8): S60-S65, 2005."},{"key":"21","doi-asserted-by":"crossref","unstructured":"23. Okyay K, Cemri M, Boyac B, Yalcn R, Cengel A. Use of long-term combined therapy with inhaled iloprost and oral sildenafil in an adult patient with eisenmenger syndrome. Cardiol Rev 13: 312-314, 2005.","DOI":"10.1097\/01.crd.0000181618.29506.1e"},{"key":"22","unstructured":"24. Habler O, Kleen M, Takenaka S, et al. Eight hour's inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology. Intensive Care Med 22: 1232-1238, 1996."},{"key":"23","doi-asserted-by":"crossref","unstructured":"25. Habler O, Kleen M, Zwissler B, et al. Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs. Intensive Care Med 22: 426-433, 1996.","DOI":"10.1007\/BF01712159"},{"key":"24","doi-asserted-by":"crossref","unstructured":"26. Mohan P, Brutsaert DL, Sys SU. Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins. Cardiovasc Res 29: 637-640, 1995.","DOI":"10.1016\/S0008-6363(96)88633-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"27. Rebsamen MC, Church DJ, Morabito D, Vallotton MB, Lang U. Role of cAMP and calcium influx in endothelin-1-induced ANP release in rat cardiomyocytes. Am J Physiol 273: E922-E931, 1997.","DOI":"10.1152\/ajpendo.1997.273.5.E922"},{"key":"26","unstructured":"28. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. Circulation 103: 544-548, 2001."},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050628"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/20\/51_51.7927\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T17:45:03Z","timestamp":1621446303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/51\/20\/51_51.7927\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":27,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.51.7927","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}